Journal
MICROORGANISMS
Volume 6, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/microorganisms6040123
Keywords
Candida; posaconazole; amphotericin B; biofilms; matrix; antifungal drug; antifungal combination; resistance; Candida glabrata
Categories
Funding
- Portuguese Foundation for Science and Technology (FCT) [UID/BIO/04469/2013 unit]
- Portuguese Foundation for Science and Technology (FCT) under the COMPETE 2020 [POCI-01-0145-FEDER-006684]
- BioTecNorte operation - European Regional Development Fund under the scope of Norte2020-Programa Operacional Regional do Norte and Celia F. Rodrigues' [SFRH/BD/93078/2013, NORTE-01-0145-FEDER-000004]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/93078/2013] Funding Source: FCT
Ask authors/readers for more resources
Candidemia cases have been increasing, especially among immunosuppressed patients. Candida glabrata is one of the most resistant Candida species, especially to the azole drugs, resulting in a high demand for therapeutic alternatives. The minimum inhibitory concentration (MIC), minimum fungicidal concentration (MFC), and minimum biofilm eradication concentration (MBEC) were determined for posaconazole (Pcz) and amphotericin B (AmB). The drug combinations of both drugs were evaluated on pre-formed biofilms of C. glabrata ATCC 2001, through XTT (2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) assay, colony forming units (CFU), crystal violet, and the fractional inhibitory concentration index (FICI). C. glabrata revealed higher susceptibility and biofilm reduction in the presence of AmB alone, but both drugs revealed a good capacity in the biomass elimination. In the majority of the tested combinations, the interactions were defined as indifferent (FICI <= 4). The combination of the two drugs does not seem to bring a clear advantage in the treatment of biofilms of C. glabrata.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available